A panel of three breast cancer experts looked at some of the big studies at ASCO 2020 and discussed treatment advances and setbacks of key data in the area of CDK4/6 inhibition, HER2-positive disease, and immunotherapy in breast cancer at a recent roundtable.
A Colorectal Cancer Clinical Roundtable: Precision Medicine, Immuno-Oncology, and Management of Adjuvant CRC
A panel of three gastrointestinal experts from the City of Hope, the Mayo Clinic, and Duke University Medical Center, led by Charles H. Weaver, MD, shared their perspectives on a key take-away emerging from several high-profile studies at ASCO 2020: less is more when it comes to chemotherapy management in treating colorectal cancer. The panel discussed highlighted data from the virtual scientific program spanning precision medicine, immuno-oncology, and the management of adjuvant colorectal cancer.
A panel of three experts, led by Dr. Brian Slomovitz of Sylvester Comprehensive Cancer Center, University of Miami Health System, discussed the expanded role of PARP inhibitors and how the new targeted agents, niraparib, olaparib, and rucaparib, are setting a new paradigm in the treatment of advanced ovarian cancer. Topics covered included a look at three landmark trials from ESMO and how they've influenced treatment regimens, incorporating BRCA and HRD testing on patients, and sequencing PARP inhibitors with and without bevacizumab as part of treatment.
James Berenson, MD, Shaji Kumar, MD, and Ruben Niesvizky, MD discuss the latest treatment trends and clinical advances in multiple myeloma including: Use of quadruplets vs. triplets, Current role of stem cell transplant, Role of maintenance therapy, Monitoring of Multiple Myeloma, Role of precision medicine